【摘要】：中藥是我國傳統(tǒng)文化中的瑰寶,是千百年醫(yī)療實踐的結(jié)晶。中藥是最具我國民族特色和獨特優(yōu)勢的產(chǎn)品,也是我國最有希望獲得國際競爭優(yōu)勢的領(lǐng)域。近年來,由于中藥市場尤其是中藥市場面臨著國際競爭國內(nèi)化、國內(nèi)競爭國際化的趨勢,我國中藥企業(yè)既面臨著機會,也面臨著挑戰(zhàn)。 一方面,隨著老齡化社會的到來,以及人們對環(huán)保意識、健康意識不斷增強,健康用藥已經(jīng)成為人們的共識。中藥作為“綠色”用藥,人們對中藥的消費量不斷攀升。與此同時,我國關(guān)于醫(yī)藥產(chǎn)業(yè)的“十二五”規(guī)劃中,首次將“支持中藥事業(yè)發(fā)展”單獨作為一節(jié)列示,為我國中藥行業(yè)的大力發(fā)展定下基調(diào)。根據(jù)“十二五”規(guī)劃,“十二五”期間我國中藥工業(yè)將保持年均12%以上的速度增長,到2015年中藥工業(yè)產(chǎn)值將達到5500億元。中藥產(chǎn)業(yè)不僅成為我國經(jīng)濟新的增長點,而且對我國產(chǎn)業(yè)結(jié)構(gòu)調(diào)整起著非常重要的作用。 另一方面,隨著世界經(jīng)濟的全球化和一體化,國外制藥企業(yè)也紛紛投入到天然植物藥市場,這些企業(yè)憑借其在資金、技術(shù)等方面優(yōu)勢,對我國中藥企業(yè)造成了極大的挑戰(zhàn)。 我國中藥企業(yè)如何去把握這種機會,去迎接這種挑戰(zhàn)?重視和加大對中藥企業(yè)的財務(wù)競爭力研究,增加企業(yè)的競爭力,是中藥企業(yè)面對市場挑戰(zhàn)的主動選擇。我們想通過“中藥上市公司財務(wù)競爭力評價研究”課題的研究,一方面,構(gòu)建中藥企業(yè)財務(wù)競爭力的評價體系,并以此評價體系,對我國中藥行業(yè)上市公司的財務(wù)競爭力進行評價和比較；另一方面,提出提升我國中藥企業(yè)財務(wù)競爭力的對策,為我國中藥企業(yè)競爭力的提升提供決策借鑒。因此,此項研究不僅具有重要的理論價值,也具有較強的實踐價值。
[Abstract]:Chinese medicine is the treasure of Chinese traditional culture and the crystallization of thousands of years of medical practice. Traditional Chinese medicine is the product with the most national characteristics and unique advantages of our country, and it is also the most promising field for our country to obtain the international competitive advantage. In recent years, the Chinese traditional medicine market, especially the traditional Chinese medicine market, is facing the trend of international competition and internationalization, so Chinese traditional medicine enterprises are faced with both opportunities and challenges. On the one hand, with the arrival of aging society, and people's awareness of environmental protection, health awareness has been strengthened, healthy drug use has become a common understanding. Chinese medicine as a "green" drug, people's consumption of traditional Chinese medicine is rising. At the same time, "supporting the development of traditional Chinese medicine" is listed as a section for the first time in the "12th Five-Year Plan" of China's pharmaceutical industry, which sets the tone for the vigorous development of Chinese traditional medicine industry. According to the 12th Five-Year Plan, China's traditional Chinese medicine industry will maintain an average annual growth rate of more than 12 percent during the 12th Five-Year Plan period, and the output value of the Chinese traditional medicine industry will reach 550 billion yuan by 2015. The traditional Chinese medicine industry not only becomes the new growth point of our country's economy, but also plays a very important role in the adjustment of our country's industrial structure. On the other hand, with the globalization and integration of the world economy, foreign pharmaceutical enterprises have also invested in the natural plant medicine market. With their advantages in capital, technology and other aspects, these enterprises have caused great challenges to Chinese traditional medicine enterprises. How do Chinese traditional medicine enterprises grasp this kind of opportunity to meet this kind of challenge? It is an active choice for traditional Chinese medicine enterprises to pay attention to and increase their financial competitiveness and increase their competitiveness in the face of market challenges. On the one hand, we want to construct the evaluation system of the financial competitiveness of traditional Chinese medicine enterprises through the research of "Evaluation Research on the Financial Competitiveness of listed Chinese Medicine companies". This paper evaluates and compares the financial competitiveness of listed companies in Chinese traditional Chinese medicine industry, and on the other hand, puts forward some countermeasures to enhance the financial competitiveness of Chinese traditional medicine enterprises, which provides a reference for the promotion of the competitiveness of Chinese traditional medicine enterprises. Therefore, this research not only has important theoretical value, but also has strong practical value.
【學(xué)位授予單位】：廣西師范大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2013
【分類號】：F275;F426.72

【參考文獻】

相關(guān)期刊論文 前10條

1 尹猛基;向希堯;;專利競爭優(yōu)勢研究綜述[J];商業(yè)研究;2008年11期

2 朱開悉;財務(wù)管理目標與企業(yè)財務(wù)核心能力[J];財經(jīng)論叢(浙江財經(jīng)學(xué)院學(xué)報);2001年05期

3 郝成林;齊榮光;郭江山;;企業(yè)財務(wù)競爭力研究[J];財會通訊(學(xué)術(shù)版);2006年03期

4 孫新憲;胡建琦;;財務(wù)核心能力研究[J];財會通訊(學(xué)術(shù)版);2006年12期

5 朱曉;;上市公司財務(wù)競爭力研究與分析[J];財會通訊(學(xué)術(shù)版);2007年07期

6 張友棠;馮自欽;;三維財務(wù)競爭力形成機理研究[J];財會通訊(綜合版);2008年08期

7 周海軍;曾理;;基于改進DEA方法的企業(yè)財務(wù)競爭力評價[J];財會通訊;2009年05期

8 郝成林;頊志芬;;財務(wù)競爭力及其構(gòu)成要素解析[J];財會月刊;2006年08期

9 吳荷青;;財務(wù)競爭力的熵權(quán)系數(shù)評價法[J];財政監(jiān)督;2008年20期

10 羅宏,陳燕;財務(wù)能力與企業(yè)核心能力的相關(guān)性[J];當代財經(jīng);2003年12期

相關(guān)碩士學(xué)位論文 前10條

1 范麗芳;基于綜合指數(shù)法的上市公司財務(wù)競爭力評價及應(yīng)用研究[D];天津財經(jīng)大學(xué);2011年

2 杜振波;山東省區(qū)域經(jīng)濟差異及其協(xié)調(diào)發(fā)展問題研究[D];山東大學(xué);2011年

3 余西平;JM公司財務(wù)核心競爭力的評價研究[D];湖南大學(xué);2010年

4 王萌;上市公司財務(wù)競爭力綜合分析與評價研究[D];北京郵電大學(xué);2012年

5 陳峰;推進中藥產(chǎn)業(yè)成為我國戰(zhàn)略產(chǎn)業(yè)的研究[D];浙江大學(xué);2002年

6 肖峻;我國中藥企業(yè)核心能力評價[D];首都經(jīng)濟貿(mào)易大學(xué);2003年

7 馬�；�;我國中藥企業(yè)的專利保護研究[D];四川大學(xué);2003年

8 郝民;從同仁堂看中藥企業(yè)國際化經(jīng)營[D];對外經(jīng)濟貿(mào)易大學(xué);2005年

9 朱劍飛;河南中藥企業(yè)競爭力提升研究[D];鄭州大學(xué);2005年

10 崔鈞;從天士力集團看中藥產(chǎn)業(yè)的國際營銷[D];昆明理工大學(xué);2006年

，

本文編號：2153756